AT-014 Osteosarcoma Vaccine
Reprinted from American Veterinarian Article - January 5th, 2018
"Osteosarcoma is the most common primary bone tumor in dogs, but a new vaccine is striving to change that narrative. Aratana Therapeutics, a company focused on innovative therapeutics for dogs and cats, announced that their Canine Osteosarcoma Vaccine, Live Listeria Vector (AT-014), has been granted a conditional license by the United States Department of Agriculture (USDA) Center for Veterinary Biologics.
The vaccine uses a listeria-based antigen delivery system that activates cytotoxic T-cells. This directs the T-cells to fight off cancer cells—capitalizing on the dog’s immune system and its ability to attack bacterial infections.
"We know that most of these dogs relapse with metastatic disease, so clearly cancer is left after chemotherapy," said Nicola J. Mason, BVetMed, PhD, assistant professor of medicine and pathobiology at the University of Pennsylvania School of Veterinary Medicine and principal investigator of clinical trials investigating the new vaccine. "And we were asking the question: Could this vaccine induce an immune response which would eliminate those remaining cancer cells?”
During a clinical trial, researchers evaluated 18 dogs with primary tumor removal and gave them 4 doses of carboplatin chemotherapy followed by the new canine osteosarcoma vaccine every 3 weeks for 3 doses. The median survival rate was 956 days with the vaccine, compared with 423 days in a historical control group."
THE TRIAL IS NOW ENROLLING PATIENTS!
We’re conducting a clinical study for dogs with osteosarcoma who have undergone amputation and chemotherapy. There are eligibility requirements for your dog to participate in the study for the conditionally licensed Canine Osteosarcoma Vaccine, Live Listeria Vector and your veterinarian will review your dog’s medical history, perform a physical exam, take thoracic radiographs, and submit routine blood and urine tests.
If you would like to learn more, please contact us at 425-697-2272 for more information.